Decoding the Cellular Response to Methylthioadenosine Uncovers Novel Targets for Chronic Liver Disease.
- 1Functional Proteomics Laboratory, National Center for Biotechnology (CNB-CSIC), Darwin 3, 28049 Madrid, Spain.
- 2Leukemia Therapy Resistance Lab, Department of Biomolecular Medicine, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium.
- 3Department of Macromolecular Structure, National Center for Biotechnology (CNB-CSIC), Darwin 3, 28049 Madrid, Spain.
Abstract
Progressive familial intrahepatic cholestasis type 3 (PFIC3), caused by MDR3 deficiency (MDR2 in mice), is a lethal pediatric liver disease characterized by early-onset persistent cholestasis, progressive fibrosis, cirrhosis, and eventual liver failure. MDR3 is a phosphatidylcholine transporter located in the canalicular membrane of hepatocytes, and its deficiency leads to the accumulation of free bile acids, which damage epithelial cells due to their detergent-like effect. Therapeutic options remain limited, highlighting the need to identify molecular drivers of disease progression and novel pharmacological strategies. To investigate the molecular alterations associated with this deficiency, our laboratory performed functional proteomic analyses in patient samples and murine hepatic organoids, revealing consistent reprogramming of one-carbon metabolism (OCM). Based on these findings, we explored the therapeutic potential and molecular mechanisms of 5'-methylthioadenosine (MTA), a metabolite involved in this pathway. Using hepatocellular carcinoma cells (PLCs), we combined quantitative shotgun proteomics with the proteome integral solubility alteration (PISA) assay to characterize functional responses and identify direct protein targets of MTA. To reinforce the physiological relevance of our findings, we extended the PISA analysis to liver protein extracts from the Mdr2-/- mouse model of chronic cholestatic injury, enabling validation of candidate target interactions observed in cellular extracts. Proteomic profiling revealed that MTA induces significant alterations in cell division processes, epigenetic regulatory networks, and energy metabolism, thereby promoting an adaptive phenotype characterized by metabolic plasticity, microenvironmental reorganization, and immunomodulation. These findings provide a robust molecular framework for understanding the hepatic response to MTA and shed new light on the mechanisms that may underlie its beneficial effects. In addition, they provide a valuable platform for further investigation of the therapeutic potential of this compound and its prospective translation into clinical practice.
Related
- Decoding the anti-adenoviral potential of Ocimum volatile organic compounds: linking chemical fingerprints to molecular targets via docking
- The Role of Telomerase in Cellular Stress Response—Therapeutic Potential of Telomerase Inhibitors
- In vitro evaluation of the osteogenic associated cellular response and antibacterial activities of Vitex negundo leaf aqueous extract
- The RNA m6A reader YTHDF2 depletion phenocopies high glucose induced-cellular stress response in diabetic kidney disease
- GLP-1 receptor agonist targets an AMPKα1-HIF1α-PFKFB3 metabolic vulnerability and enhances Lenvatinib response in hepatocellular carcinoma
BibTeX
@article{blazquezgarcia2026decoding,
title = {{Decoding the Cellular Response to Methylthioadenosine Uncovers Novel Targets for Chronic Liver Disease.}},
author = {Irene Blázquez-García and Laura Guerrero and Mary Dayne S Tai and Américo Cerqueira and Ana Cuervo and Alberto Paradela and Fernando J Corrales},
journal = {Cells},
year = {2026},
month = sep,
doi = {10.3390/cells15191720},
url = {https://europepmc.org/article/MED/42882418},
note = {CC BY},
}
RIS
TY - JOUR
TI - Decoding the Cellular Response to Methylthioadenosine Uncovers Novel Targets for Chronic Liver Disease.
AU - Irene Blázquez-García
AU - Laura Guerrero
AU - Mary Dayne S Tai
AU - Américo Cerqueira
AU - Ana Cuervo
AU - Alberto Paradela
AU - Fernando J Corrales
PY - 2026
DA - 2026/09/22
JO - Cells
DO - 10.3390/cells15191720
UR - https://europepmc.org/article/MED/42882418
AB - Progressive familial intrahepatic cholestasis type 3 (PFIC3), caused by MDR3 deficiency (MDR2 in mice), is a lethal pediatric liver disease characterized by early-onset persistent cholestasis, progressive fibrosis, cirrhosis, and eventual liver failure. MDR3 is a phosphatidylcholine transporter located in the canalicular membrane of hepatocytes, and its deficiency leads to the accumulation of free bile acids, which damage epithelial cells due to their detergent-like effect. Therapeutic options remain limited, highlighting the need to identify molecular drivers of disease progression and novel pharmacological strategies. To investigate the molecular alterations associated with this deficiency, our laboratory performed functional proteomic analyses in patient samples and murine hepatic organoids, revealing consistent reprogramming of one-carbon metabolism (OCM). Based on these findings, we explored the therapeutic potential and molecular mechanisms of 5'-methylthioadenosine (MTA), a metabolite involved in this pathway. Using hepatocellular carcinoma cells (PLCs), we combined quantitative shotgun proteomics with the proteome integral solubility alteration (PISA) assay to characterize functional responses and identify direct protein targets of MTA. To reinforce the physiological relevance of our findings, we extended the PISA analysis to liver protein extracts from the Mdr2-/- mouse model of chronic cholestatic injury, enabling validation of candidate target interactions observed in cellular extracts. Proteomic profiling revealed that MTA induces significant alterations in cell division processes, epigenetic regulatory networks, and energy metabolism, thereby promoting an adaptive phenotype characterized by metabolic plasticity, microenvironmental reorganization, and immunomodulation. These findings provide a robust molecular framework for understanding the hepatic response to MTA and shed new light on the mechanisms that may underlie its beneficial effects. In addition, they provide a valuable platform for further investigation of the therapeutic potential of this compound and its prospective translation into clinical practice.
SN - 2073-4409
ER -